McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368. (Erratum in: Eur Heart J. 2021 Dec 21;42(48):4901. 10.1093/eurheartj/ehab670)

Article  CAS  PubMed  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA/ACC/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79:1757–1780. https://doi.org/10.1016/j.jacc.2021.12.011

Article  PubMed  Google Scholar 

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717. https://doi.org/10.1056/NEJM199909023411001

Article  CAS  PubMed  Google Scholar 

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. https://doi.org/10.1056/NEJMoa1009492

Article  CAS  PubMed  Google Scholar 

Eworuke E, Cosgrove A, Her QL, Lyons JG, Martin D, Adimadhyam S (2022) Spironolactone utilization among patients with reduced and preserved ejection fraction heart failure. Pharmacoepidemiology 1(3):89–100. https://doi.org/10.3390/pharma1030009

Article  Google Scholar 

Querejeta R et al (2004) Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110:1263–1268

Article  CAS  PubMed  Google Scholar 

Borlaug BA, Paulus WJ (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32(6):670–679. https://doi.org/10.1093/eurheartj/ehq426

Article  PubMed  Google Scholar 

Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O’Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M (2014) Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2(2):97–112. https://doi.org/10.1016/j.jchf.2013.10.006

Article  PubMed  PubMed Central  Google Scholar 

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392. https://doi.org/10.1056/NEJMoa1313731

Article  CAS  PubMed  Google Scholar 

Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1):34–42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255

Article  CAS  PubMed  Google Scholar 

de Denus S, O’Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL (2017) Spironolactone Metabolites in TOPCAT - new insights into regional variation. N Engl J Med 376(17):1690–1692. https://doi.org/10.1056/NEJMc1612601

Article  PubMed  PubMed Central  Google Scholar 

Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, Yarde M, Wang Z, Bhattacharya PT, Chirinos DA, Prenner S, Zamani P, Seiffert DA, Car BD, Gordon DA, Margulies K, Cappola T, Chirinos JA (2020) Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail 8(3):172–184. https://doi.org/10.1016/j.jchf.2019.09.009

Article  PubMed  PubMed Central  Google Scholar 

Kolkhof P, Joseph A, Kintscher U (2021) Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders—new perspectives for combination therapy. Pharmacol Res 172:105859. https://doi.org/10.1016/j.phrs.2021.105859

Article  CAS  PubMed  Google Scholar 

Chang J, Ambrosy AP, Vardeny O, Van Spall HGC, Mentz RJ, Sauer AJ (2024) Mineralocorticoid antagonism in heart failure: established and emerging therapeutic role. JACC Heart Fail S2213–1779(24):00606–00611. https://doi.org/10.1016/j.jchf.2024.08.007

Article  CAS  Google Scholar 

Kintscher U, Bakris GL, Kolkhof P (2022) Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 179(13):3220–3234. https://doi.org/10.1111/bph.15747

Article  CAS  PubMed  Google Scholar 

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G, FIDELIO-DKD Investigators (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219–2229. https://doi.org/10.1056/NEJMoa2025845

Article  CAS  PubMed  Google Scholar 

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM, FIGARO-DKD Investigators (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252–2263. https://doi.org/10.1056/NEJMoa2110956

Article  CAS  PubMed  Google Scholar 

Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474–484. https://doi.org/10.1093/eurheartj/ehab777

Article  CAS  PubMed  Google Scholar 

Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL, FIDELIO-DKD Investigators (2022) Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial. J Am Soc Nephrol 33(1):225–237. https://doi.org/10.1681/ASN.2021070942

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist bAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double- blind trial. Eur Heart J 34:2453–2463. https://doi.org/10.1093/Eurheartj/Eht187

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solomon SD, McMurray JJV et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa2407107

Article  PubMed  Google Scholar